title: Pharmacological strategies aimed at reducing complications associated with coronary artery bypass graft surgery.
authors.forename: Jamie Y
authors.initials: JY
authors.lastname: Jeremy
authors.forename: Kai
authors.initials: K
authors.lastname: Zacharowski
authors.forename: Nilima
authors.initials: N
authors.lastname: Shukla
authors.forename: Song
authors.initials: S
authors.lastname: Wan
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D054697:Cytostatic Agents / Q000627:therapeutic use; D054855:Drug-Eluting Stents; D011464:Epoprostenol / Q000627:therapeutic use; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000502:physiology; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control; D012501:Saphenous Vein / Q000637:transplantation*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000975:Antioxidants; D054697:Cytostatic Agents; D020030:Nitric Oxide Donors; D010726:Phosphodiesterase Inhibitors; D011464:Epoprostenol